Pharmaceutical companies in Argentina

Generics/General | Posted 08/07/2022 post-comment4 Post your comment

Argentina has an important pharmaceutical sector, being the third largest market in Latin America after Brazil and Mexico. Pharmaceutical companies from Denmark, France, Germany, Switzerland, the UK and the US are stablished in Argentina. Argentine market has extensive experience in the incorporation of foreign investments for the sector as well as offers multiple business opportunities.

150 AA010692

Argentina has around 65 biotech companies working on human health, showing strengths in the development of generics and biosimilars. Over a dozen of these companies are exporting biosimilars, primarily to other countries in the region and to Asia. Sales to China, India and Vietnam increased by 179 per cent between 2003 and 2017. Some of these companies also manufacture their products in Asia. For example, Bagó, through a joint venture, produces biosimilars in Pakistan. Others such as BioNovis SA fill and finish local products that were developed abroad. The Insud group for instance, entered an agreement with AstraZeneca and Liomont of Mexico to produce a COVID-19 vaccines [1].

In Argentina, local firms play a leading role in manufacturing pharmaceuticals. Measured by their share of market sales, only two out of the top 10 pharmaceutical companies operating in Argentina (Sanofi and Bayer) are foreign multinationals [2]. This market is characterized by a high degree of concentration, around 20 laboratories account for 70% of the market.

Some of the most important domestic pharmaceutical companies in Argentina are shown in Table 1.

Table 1: Top domestic pharmaceutical companies in Argentina
Pharma company Manufactures Exporting countries
Roemmers Generics – Other countries in LA: Mexico, Brazil, Ecuador, Peru, Colombia, Chile, Venezuela and Paraguay 
– Western Europe
– Asia
Gador Biologicals, branded generics, APIs – Other countries in LA
– Western Europe
– Asia
Bagó Generics – Other countries in LA
– Western Europe
– Asia
Elea Phoenix mAbs, therapeutic vaccines – Other countries in LA
– Western Europe
– Asia
Grupo Insud (Chemo, Exeltis, mAbxience) Generics, biosimilars, APIs – Other countries in LA
– Western Europe
– Asia
Laboratorio Pablo Cassará SRL Generics – Other countries in LA
– Western Europe
– Asia
APIs: active pharmaceutical ingredients; LA: Latin America; mAbs: monoclonal antibodies.


From the pharmaceutical companies described in Table 1, only Elea Phoenix and mAbxience produce biosimilars (two monoclonal antibodies). Some of them only produce off-patent biologicals approved prior to the ANMAT provisions regulating biosimilars in 2011, so they are not biosimilars because they have not undergone the necessary studies to achieve this qualification.

This article belongs to the series of articles which discuss the study results of pharmaceuticals development in other countries of Latin America and the Caribbean like Brazil, Chile, Colombia, Mexico, Costa Rica and Cuba.

Related articles
Nomenclature of biologicals and biosimilars in Argentina 

Argentinian gastroenterologist groups issued position statement on biosimilar use 

Regulatory landscape for similar biotherapeutic products in Latin America


The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View this week’s headline article: Directrices revisadas de la OMS para los biosimilares: antecedentes científicos

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.


Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: Directrices revisadas de la OMS para los biosimilares: antecedentes científicos

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. Vargas V, Rama M, Singh R. Pharmaceuticals in Latin America and the Caribbean: players, access, and innovation across diverse models. 3 January 2022. World Bank. Available from: License: CC BY 3.0 IGO.”
2. GaBI Online - Generics and Biosimilars Initiative. Pharmaceutical companies in Latin America and the Caribbean[]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Jul 8]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (4)
Post your comment
Posted 26/10/2022 by Maroua Y, GaBI Online Editorial Office
Response to ‘Error in data’

Dear Martina Almeide,
Thank you for your valuable comments received on 5 October 2022. We appreciate that you are letting us know. Please be advised we have updated the information of this article, kindly continue with your valuable comments to GaBI Online.
Best Regards, Maroua

Posted 26/10/2022 by Maroua Y, GaBI Online Editorial Office
Response to ‘Empresas farmacéuticas en Argentina’

Dear Pablo Matar,
Thank you for your valuable comments received on 11 July 2022. We appreciate that you are letting us know. Please be advised we have updated the information of this article, kindly continue with your valuable comments to GaBI Online.
Best Regards, Maroua

Posted 05/10/2022 by Martina Almeide
Error in data

This article has lot's of errors, neither Roemmers, Gador, Bagó or Cassara produces or markets Biosimilars or Innovative products.

Posted 11/07/2022 by Pablo Matar
Empresas farmacéuticas en Argentina

Este breve posteo contiene muchos errores e inexactitudes que son muy importantes de destacar. En primer lugar, en Argentina no existe una legislación para medicamentos genéricos, por lo tanto ninguna de las empresas mencionadas produce genéricos. La mayoría son similares. En segundo lugar, de las empresas mencionadas, solamente Elea Phoenix y Mabxience (ambas pertenecen al Grupo Insud), producen biosimilares (dos anticuerpos monoclonales); el resto no. Algunas de ellas solo producen biológicos aprobados con anterioridad a las disposiciones de ANMAT que regulan biosimilares, del año 2011, por lo tanto no son biosimilares porque no han sido sometidos a los estudios necesarios para conseguir esa calificación. El Editor responsable de autorizar estos textos para ser publicados debería revisar con mayor cautela la bibliografía.

Related content
Generic drug growth in Brazil and Venezuela
53 MD002445
Generics/General Posted 15/09/2023
Pharmaceutical manufacturing companies in Brazil
91 AA007225
Generics/General Posted 26/08/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010